Company Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease.
The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia.
It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target.
The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
| Country | United Kingdom |
| Founded | 1992 |
| IPO Date | May 12, 1993 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 89,900 |
| CEO | Pascal Soriot |
Contact Details
Address: 1 Francis Crick Avenue, Cambridge Biomedical Campus Cambridge, CB2 0AA United Kingdom | |
| Phone | 44 20 3749 5000 |
| Website | astrazeneca.com |
Stock Details
| Ticker Symbol | AZN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000901832 |
| CUSIP Number | 046353108 |
| ISIN Number | US0463531089 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Pascal Soriot D.V.M., M.B.A. | Chief Executive Officer and Executive Director |
| Dr. Aradhana Sarin M.D. | Chief Financial Officer and Executive Director |
| Pam P. Cheng | Executive Vice President of Global opt. and IT, Chief Sust. Officer and Member of External Sust.Adv. Board |
| Andrew P. Barnett | Head of Investor Relations |
| Gonzalo Vina | Head of Global Media Relations |
| Dr. Ruud Dobber Ph.D. | Executive Vice-President of BioPharmaceuticals Business Unit |
| Dr. Susan Mary Galbraith M.D., Ph.D. | Executive Vice President of Oncology Research and Development |
| Leon Wang | Executive Vice President of International and China President |
| Iskra Reic | Executive Vice-President of Vaccines and Immune Therapies |
| David Fredrickson | Executive Vice-President of Oncology Business Unit |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | 6-K | Report of foreign issuer |
| Nov 18, 2024 | 6-K | Report of foreign issuer |
| Nov 15, 2024 | 6-K | Report of foreign issuer |
| Nov 15, 2024 | 6-K | Report of foreign issuer |
| Nov 13, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Nov 8, 2024 | 6-K | Report of foreign issuer |